150 related articles for article (PubMed ID: 28467003)
1. Knowledge and expectations of direct support professionals towards effects of psychotropic drug use in people with intellectual disabilities.
de Kuijper G; van der Putten AAJ
J Appl Res Intellect Disabil; 2017 Dec; 30 Suppl 1():1-9. PubMed ID: 28467003
[TBL] [Abstract][Full Text] [Related]
2. An open label discontinuation trial of long-term used off-label antipsychotic drugs in people with intellectual disability: The influence of staff-related factors.
de Kuijper GM; Hoekstra PJ
J Appl Res Intellect Disabil; 2019 Mar; 32(2):313-322. PubMed ID: 30264420
[TBL] [Abstract][Full Text] [Related]
3. Physicians' reasons not to discontinue long-term used off-label antipsychotic drugs in people with intellectual disability.
de Kuijper GM; Hoekstra PJ
J Intellect Disabil Res; 2017 Oct; 61(10):899-908. PubMed ID: 28560761
[TBL] [Abstract][Full Text] [Related]
4. Support staff's perceptions of discontinuing antipsychotics in people with intellectual disabilities in residential care: A mixed-method study.
Kleijwegt B; Pruijssers A; de Jong-Bakker L; de Haan K; van Os-Medendorp H; van Meijel B
J Appl Res Intellect Disabil; 2019 Jul; 32(4):861-870. PubMed ID: 30790388
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and the trajectory of psychotropic medication use in general and antipsychotics in particular among adults with an intellectual disability who exhibit aggressive behaviour.
Deb S; Unwin G; Deb T
J Intellect Disabil Res; 2015 Jan; 59(1):11-25. PubMed ID: 24450426
[TBL] [Abstract][Full Text] [Related]
6. Effects of controlled discontinuation of long-term used antipsychotics for behavioural symptoms in individuals with intellectual disability.
de Kuijper G; Evenhuis H; Minderaa RB; Hoekstra PJ
J Intellect Disabil Res; 2014 Jan; 58(1):71-83. PubMed ID: 23046144
[TBL] [Abstract][Full Text] [Related]
7. Psychotropic drugs intake in people aging with intellectual disability: Prevalence and predictors.
García-Domínguez L; Navas P; Verdugo MÁ; Arias VB; Gómez LE
J Appl Res Intellect Disabil; 2022 Sep; 35(5):1109-1118. PubMed ID: 35384179
[TBL] [Abstract][Full Text] [Related]
8. An Open-Label Discontinuation Trial of Long-Term, Off-Label Antipsychotic Medication in People With Intellectual Disability: Determinants of Success and Failure.
de Kuijper GM; Hoekstra PJ
J Clin Pharmacol; 2018 Nov; 58(11):1418-1426. PubMed ID: 29920689
[TBL] [Abstract][Full Text] [Related]
9. Direct service staff and their perceptions of psychotropic medication in non-institutional settings for people with intellectual disability.
Christian L; Snycerski SM; Singh NN; Poling A
J Intellect Disabil Res; 1999 Apr; 43 ( Pt 2)():88-93. PubMed ID: 10221788
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of the 'Who's Challenging Who' support staff training intervention to improve attitudes and empathy towards adults with intellectual disability and challenging behaviours: study protocol for a cluster randomised controlled trial.
Randell E; Hastings RP; McNamara R; Knight R; Gillespie D; Taylor Z
Trials; 2017 Oct; 18(1):460. PubMed ID: 28982380
[TBL] [Abstract][Full Text] [Related]
11. The UK psychiatrists' experience of rationalising antipsychotics in adults with intellectual disabilities: A qualitative data analysis of free-text questionnaire responses.
Shoumi Deb S; Limbu B; Nancarrow T; Gerrard D; Shankar R
J Appl Res Intellect Disabil; 2023 May; 36(3):594-603. PubMed ID: 36808782
[TBL] [Abstract][Full Text] [Related]
12. Exploring barriers and facilitators in the implementation and use of guideline recommendations on antipsychotic drug prescriptions for people with intellectual disability.
Ramerman L; Hoekstra PJ; de Kuijper G
J Appl Res Intellect Disabil; 2018 Nov; 31(6):1062-1070. PubMed ID: 29923275
[TBL] [Abstract][Full Text] [Related]
13. Professionals' perceptions of psychotropic medication in residential facilities for individuals with mental retardation.
Singh NN; Ellis CR; Donatelli LS; Williams DE; Ricketts RW; Goza AB; Perlman N; Everly DE; Best AM; Singh YN
J Intellect Disabil Res; 1996 Feb; 40 ( Pt 1)():1-7. PubMed ID: 8930051
[TBL] [Abstract][Full Text] [Related]
14. Receipt of psychotropic medication by people with intellectual disability in residential settings.
Robertson J; Emerson E; Gregory N; Hatton C; Kessissoglou S; Hallam A
J Intellect Disabil Res; 2000 Dec; 44 ( Pt 6)():666-76. PubMed ID: 11115021
[TBL] [Abstract][Full Text] [Related]
15. Adverse events and the relation with quality of life in adults with intellectual disability and challenging behaviour using psychotropic drugs.
Scheifes A; Walraven S; Stolker JJ; Nijman HL; Egberts TC; Heerdink ER
Res Dev Disabil; 2016; 49-50():13-21. PubMed ID: 26647003
[TBL] [Abstract][Full Text] [Related]
16. Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study.
Sheehan R; Hassiotis A; Walters K; Osborn D; Strydom A; Horsfall L
BMJ; 2015 Sep; 351():h4326. PubMed ID: 26330451
[TBL] [Abstract][Full Text] [Related]
17. Physical-activity support for people with intellectual disabilities: development of a tool to measure behavioural determinants in direct support professionals.
Bossink LWM; van der Putten AAJ; Steenbergen HA; Vlaskamp C
J Intellect Disabil Res; 2019 Oct; 63(10):1193-1206. PubMed ID: 31106932
[TBL] [Abstract][Full Text] [Related]
18. Psychotropic drug use with successful and unsuccessful community placed developmentally disabled groups.
Harder SR; Kalachnik JE; Jensen MA; Feltz J
Res Dev Disabil; 1987; 8(2):191-202. PubMed ID: 2890188
[TBL] [Abstract][Full Text] [Related]
19. [Psychotropic drug prescription to people with intellectual disability in GP practices].
Bakker-van Gijssel EJ; Leusink GL
Ned Tijdschr Geneeskd; 2015; 159():A9754. PubMed ID: 26629605
[TBL] [Abstract][Full Text] [Related]
20. Trends in the use of psychotropic drugs in people with intellectual disability in Taiwan: a nationwide outpatient service study, 1997-2007.
Hsu SW; Chiang PH; Chang YC; Lin JD; Tung HJ; Chen CY
Res Dev Disabil; 2014 Feb; 35(2):364-72. PubMed ID: 24333807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
